MilliporeSigma
All Photos(1)

Documents

S1764

Sigma-Aldrich

Complement sera human

lyophilized powder

Sign Into View Organizational & Contract Pricing

MDL number:
NACRES:
NA.61

biological source

human

Quality Level

form

lyophilized powder

origin

USA origin

technique(s)

cell culture | mammalian: suitable

impurities

virus, tested

shipped in

dry ice

storage temp.

−20°C

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
S7764C9473C8788
Sigma-Aldrich

Sigma-Aldrich

S1764

Complement sera human

form

lyophilized powder

form

lyophilized powder

form

aqueous solution

form

solution

origin

USA origin

origin

-

origin

-

origin

-

technique(s)

cell culture | mammalian: suitable

technique(s)

cell culture | embryo: suitable, cell culture | mammalian: suitable

technique(s)

-

technique(s)

activity assay: suitable

impurities

virus, tested

impurities

-

impurities

-

impurities

infectious agent, tested

shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

General description

Complement serum is prepared from pooled human plasma and lyophilized from the amount of serum indicated on the label.

Application

Complement sera human has been used:
  • to incubate DLD-1 or SW-620 cells to quantify C5a release
  • in multiplex bead antibody-binding assay to assay C3d
  • in complement-dependent cytotoxicity assay

Complement sera human has been used:
  • to incubate DLD-1 or SW-620 cells to quantify C5a release
  • in multiplex bead antibody-binding assay to assay C3d
  • in complement-dependent cytotoxicity assay

The activity of complement sera can be determined by hemolytic assays in vitro.

Physical form

Lyophilized powder from indicated amount of serum

Analysis Note

Hemolytic titer (CH50 units per ml) is determined by method of Kabat and Mayer. Actual titer given on label.

Disclaimer

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Harini Natarajan et al.
mBio, 12(2) (2021-04-22)
Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but the antibody characteristics that contribute to efficacy remain poorly understood. This study analyzed plasma samples from 126 eligible convalescent blood donors in addition to 15 naive individuals, as
Lisa Tomasi et al.
Open forum infectious diseases, 9(11), ofac554-ofac554 (2022-12-06)
The basis of the less severe clinical presentation of coronavirus disease 2019 (COVID-19) in children as compared with adults remains incompletely understood. Studies have suggested that a more potent boosting of immunity to endemic common cold coronaviruses (HCoVs) may protect
Yui Suzuki et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(14), 4388-4399 (2019-04-26)
The anti-CCR4 mAb, mogamulizumab, offers therapeutic benefit to patients with adult T-cell leukemia-lymphoma (ATL), but skin-related adverse events (AE) such as erythema multiforme occur frequently. The purpose of this study was to determine the mechanisms by which mogamulizumab causes skin-related
Chiaki Kawabata et al.
Biological & pharmaceutical bulletin, 44(2), 219-224 (2021-02-02)
Baculovirus vectors (BVs) are safely able to transduce foreign genes and express them in mammalian cells. However, the transduction activity of BVs is strongly reduced by the attack of serum complement, which is one of the major obstacles in the
Helen Kotanides et al.
Cancer immunology research, 8(10), 1300-1310 (2020-09-03)
The programmed cell death protein 1 receptor (PD-1) and programmed death ligand 1 (PD-L1) coinhibitory pathway suppresses T-cell-mediated immunity. We hypothesized that cotargeting of PD-1 and PD-L1 with a bispecific antibody molecule could provide an alternative therapeutic approach, with enhanced

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service